Dafne Müller

发表

Combining Antibody-Directed Presentation of IL-15 and 4-1BBL in a Trifunctional Fusion Protein for Cancer Immunotherapy

R. Kontermann, Nora Hornig, A. Bondarieva, 2013, Molecular Cancer Therapeutics.

An Antibody Fusion Protein for Cancer Immunotherapy Mimicking IL-15 trans-Presentation at the Tumor Site

R. Kontermann, Nora Hornig, Vanessa Kermer, 2012, Molecular Cancer Therapeutics.

Murine endoglin-specific single-chain Fv fragments for the analysis of vascular targeting strategies in mice.

R. Kontermann, M. Quintanilla, A. Sichelstiel, 2008, Journal of immunological methods.

Targeting of epidermal growth factor receptor (EGFR)-expressing tumor cells with sterically stabilized affibody liposomes (SAL).

R. Kontermann, F. Frejd, M. Rothdiener, 2009, Bioconjugate chemistry.

Targeting Co-Stimulatory Receptors of the TNF Superfamily for Cancer Immunotherapy

Dafne Müller, 2022, BioDrugs.

A Novel Antibody–4-1BBL Fusion Protein for Targeted Costimulation in Cancer Immunotherapy

R. Kontermann, Katharina Frey, Dafne Müller, 2008, Journal of immunotherapy.

Tumor-targeted costimulation with antibody-fusion proteins improves bispecific antibody-mediated immune response in presence of immunosuppressive factors

R. Kontermann, D. Müller, Sabrina Sapski, 2017, Oncoimmunology.

Targeted delivery of SiRNA to CD33-positive tumor cells with liposomal carrier systems.

R. Kontermann, O. Heidenreich, D. Müller, 2010, Journal of controlled release : official journal of the Controlled Release Society.

miR149 functions as a tumor suppressor by controlling breast epithelial cell migration and invasion.

Monilola A. Olayioye, M. Boerries, H. Busch, 2014, Cancer research.

miR-149 functions as a tumor suppressor by controlling breast epithelial cell migration and invasion

Monilola A. Olayioye, M. Boerries, H. Busch, 2014 .

N-Glycosylation as Novel Strategy to Improve Pharmacokinetic Properties of Bispecific Single-chain Diabodies*

R. Kontermann, F. Hanisch, R. Stork, 2008, Journal of Biological Chemistry.

Antibody fusions with immunomodulatory proteins for cancer therapy.

Dafne Müller, 2015, Pharmacology & therapeutics.

Improved Pharmacokinetics of Recombinant Bispecific Antibody Molecules by Fusion to Human Serum Albumin*

R. Kontermann, B. Meissburger, Anette C. Karle, 2007, Journal of Biological Chemistry.

Generation of a FasL-based Proapoptotic Fusion Protein Devoid of Systemic Toxicity due to Cell-surface Antigen-restricted Activation*

H. Wajant, K. Pfizenmaier, D. Müller, 2003, Journal of Biological Chemistry.

Single-chain Fv immunoliposomes for the targeting of fibroblast activation protein-expressing tumor stromal cells

R. Kontermann, D. Müller, Patrick Baum, 2007, Journal of drug targeting.

Evaluating combinations of costimulatory antibody–ligand fusion proteins for targeted cancer immunotherapy

R. Kontermann, Nora Hornig, D. Müller, 2013, Cancer Immunology, Immunotherapy.

Bispecific Antibodies for Cancer Immunotherapy

R. Kontermann, D. Müller, Dafne Müller, 2010, BioDrugs.

IL15-Based Trifunctional Antibody-Fusion Proteins with Costimulatory TNF-Superfamily Ligands in the Single-Chain Format for Cancer Immunotherapy

R. Kontermann, Sarah Ring, Nadine Beha, 2019, Molecular Cancer Therapeutics.

Antibody–Cytokine Fusion Proteins for Cancer Immunotherapy: An Update on Recent Developments

Dafne Müller, 2013, BioDrugs.

The effects of affinity and valency of an albumin-binding domain (ABD) on the half-life of a single-chain diabody-ABD fusion protein.

Kirstin A. Zettlitz, R. Kontermann, Jonas Hopp, 2010, Protein engineering, design & selection : PEDS.

Biodistribution of a Bispecific Single-chain Diabody and Its Half-life Extended Derivatives*

R. Kontermann, B. Robert, R. Stork, 2009, The Journal of Biological Chemistry.

Tumor-specific Crosslinking of GITR as Costimulation for Immunotherapy

L. Old, D. Müller, H. Shiku, 2010, Journal of immunotherapy.

Influence of antigen density and immunosuppressive factors on tumor-targeted costimulation with antibody-fusion proteins and bispecific antibody-mediated T cell response

R. Kontermann, Sabrina Sapski, Nadine Beha, 2020, Cancer Immunology, Immunotherapy.

Combination of a Bispecific Antibody and Costimulatory Antibody-Ligand Fusion Proteins for Targeted Cancer Immunotherapy

R. Kontermann, Nora Hornig, Katharina Frey, 2012, Journal of immunotherapy.

Advancing targeted co-stimulation with antibody-fusion proteins by introducing TNF superfamily members in a single-chain format

R. Kontermann, Sarah Ring, Sina Fellermeier, 2016, Oncoimmunology.

Generation of immunoliposomes using recombinant single-chain Fv fragments bound to Ni-NTA-liposomes

R. Kontermann, D. Müller, A. Fahr, 2005, Journal of drug targeting.

Diabodies, Single-Chain Diabodies, and Their Derivatives

R. Kontermann, D. Müller, Dafne Müller, 2011 .

Production, Purification, and Characterization of Antibody-TNF Superfamily Ligand Fusion Proteins.

M. Siegemund, Nadine Beha, Dafne Müller, 2018, Methods in molecular biology.

Duokines: a novel class of dual-acting co-stimulatory molecules acting in cis or trans

U. Şahin, R. Kontermann, K. Pfizenmaier, 2018, Oncoimmunology.

Humanization of a Mouse Monoclonal Antibody Directed Against a Cell Surface-Exposed Epitope of Membrane-Associated Heat Shock Protein 70 (Hsp70)

R. Kontermann, Dafne Müller, K. Zettlitz, 2010, Molecular biotechnology.

A Humanized Tumor Necrosis Factor Receptor 1 (TNFR1)-specific Antagonistic Antibody for Selective Inhibition of Tumor Necrosis Factor (TNF) Action

P. Scheurich, R. Kontermann, K. Pfizenmaier, 2008, Journal of immunotherapy.

Recombinant bispecific antibodies for cellular cancer immunotherapy.

R. Kontermann, Dafne Müller, 2007, Current opinion in molecular therapeutics.

Novel single-chain Fv' formats for the generation of immunoliposomes by site-directed coupling.

R. Kontermann, A. Kolbe, J. Pleiss, 2008, Bioconjugate chemistry.

A novel tri-functional antibody fusion protein with improved pharmacokinetic properties generated by fusing a bispecific single-chain diabody with an albumin-binding domain from streptococcal protein G.

R. Kontermann, Roland Stork, Dafne Müller, 2007, Protein engineering, design & selection : PEDS.

Antibody–Cytokine Fusion Proteins for Cancer Immunotherapy: An Update on Recent Developments

Dafne Müller, 2014, BioDrugs.

Optimized CD19/CD22/CD3 antibody.

Dafne Müller, 2022, Blood.

Mechanosensory feedback loops during chronic inflammation

Andrew G. Clark, Sarbari Saha, Dafne Müller, 2023, Frontiers in cell and developmental biology.

Tumor-specific Crosslinking of GITR as Costimulation for Immunotherapy

L. Old, H. Shiku, A. Zippelius, 2010, Journal of immunotherapy.

A Humanized Tumor Necrosis Factor Receptor 1 (TNFR1)-specific Antagonistic Antibody for Selective Inhibition of Tumor Necrosis Factor (TNF) Action

P. Scheurich, R. Kontermann, K. Pfizenmaier, 2008, Journal of immunotherapy.

N-Glycosylation as Novel Strategy to Improve Pharmacokinetic Properties of Bispecific Single-chain Diabodies*

R. Kontermann, F. Hanisch, R. Stork, 2008, Journal of Biological Chemistry.

Restoration of membrane TNF-like activity by cell surface targeting and matrix metalloproteinase-mediated processing of a TNF prodrug

H. Wajant, A. Menrad, K. Pfizenmaier, 2006, Cell Death and Differentiation.

Targeted cancer immunotherapy

Dafne Müller, 2012, Oncoimmunology.